← Eichor
Condition: Refractory Osteosarcoma Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Refractory Osteosarcoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory
Phase 1 · 2 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT03721068Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies
Phase 1 · 10 location(s) · Circle Pharma · NCT06577987Apatinib Combined With Liposomal Irinotecan for Refractory or Metastatic Osteosarcoma
Phase 1/Phase 2 · 1 location(s) · Peking University People's Hospital · NCT07479732Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors
Phase 1 · 1 location(s) · Stanford University · NCT06500819Weekly Irinotecan Liposomes in Recurrent or Refractory Ewing Sarcoma
Phase 1 · 3 location(s) · Peking University People's Hospital · NCT06340204Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
Phase 1/Phase 2 · 22 location(s) · Milton S. Hershey Medical Center · NCT06541262Hypofractionated Radiation in Combination With B7-H3-CAR T Cells for Pediatric Patients With Relapsed/Refractory Sarcoma
Phase 1 · 1 location(s) · St. Jude Children's Research Hospital · NCT07222735NKG2D.Zeta-NK Cell Conditioning With C7R.GD2.CAR-T Cells for Patients With Relapsed or Refractory Osteosarcoma or Neurob
Phase 1 · 1 location(s) · Baylor College of Medicine · NCT07211737ARTEMIS-002: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other Sarcomas
Phase 2 · 11 location(s) · Hansoh BioMedical R&D Company · NCT05830123Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
Phase 1/Phase 2 · 10 location(s) · St. Jude Children's Research Hospital · NCT04901702Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas
Phase 1/Phase 2 · 12 location(s) · Milton S. Hershey Medical Center · NCT06465199Tegavivint With Gemcitabine in Patients With Relapsed or Refractory Osteosarcoma
Phase 1 · 1 location(s) · Emory University · NCT07144254Atezolizumab and Cabozantinib for the Treatment of Adolescents and Young Adults With Recurrent or Metastatic Osteosarcom
Phase 2 · 2 location(s) · M.D. Anderson Cancer Center · NCT05019703Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumor
Phase 1 · 1 location(s) · University of Wisconsin, Madison · NCT02508038Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Phase 2 · 3 location(s) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · NCT01804634Trastuzumab Deruxtecan (DS-8201a) for the Treatment of Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplast
Phase 1/Phase 2 · 28 location(s) · National Cancer Institute (NCI) · NCT04616560DFMO Maintenance for Patients With Relapsed/Refractory Ewing Sarcoma or Osteosarcoma
Phase 1/Phase 2 · 1 location(s) · Montefiore Medical Center · NCT06892678Losartan + Sunitinib in Treatment of Osteosarcoma
Phase 1 · 4 location(s) · University of Colorado, Denver · NCT03900793Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)
Phase 1 · 2 location(s) · Children's National Research Institute · NCT07172958Genetically Engineered Cells (FH-FOLR1 ST CAR T Cells) for the Treatment of Advanced Refractory or Recurrent/Progressive
Phase 1 · 1 location(s) · Fred Hutchinson Cancer Center · NCT07227571Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treat
Phase 1/Phase 2 · 1 location(s) · Fundación de investigación HM · NCT06607692AOH1996 for the Treatment of Refractory Solid Tumors
Phase 1 · 3 location(s) · City of Hope Medical Center · NCT05227326Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Phase 1/Phase 2 · 21 location(s) · Children's Oncology Group · NCT04851119Evaluation of Xaluritamig in Adults, Adolescents and Children With Relapsed or Refractory Ewing Sarcoma (EWS)
Phase 1 · 8 location(s) · Amgen · NCT07297979Allogeneic Expanded Gamma Delta T Cells With GD2 Chemoimmunotherapy in Relapsed /Refractory Neuroblastoma or Refractory/
Phase 1 · 1 location(s) · Emory University · NCT05400603Disulfiram With Copper Gluconate and Liposomal Doxorubicin in Treatment-Refractory Sarcomas
Phase 1 · 1 location(s) · Case Comprehensive Cancer Center · NCT05210374Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies
Phase 1 · 1 location(s) · New York Medical College · NCT04308330Study to Assess Safety and Efficacy of Vactosertib in Adolescents and Adults With Recurrent, Refractory or Progressive O
Phase 1/Phase 2 · 3 location(s) · MedPacto, Inc. · NCT05588648Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma
Phase 1/Phase 2 · 15 location(s) · Jazz Pharmaceuticals · NCT05734066Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adol
Phase 1/Phase 2 · 3 location(s) · David S Shulman, MD · NCT06709495
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.